Global Tissue Engineered Skin Substitutes Market Size, Share, Forecast Report, 2020-2027

The global tissue engineered skin substitutes market size was valued at USD 660.1 million in 2019 and is expected to grow at a compound annual growth rate (CAGR) of 4.7% from 2020 to 2027. The demand for tissue engineered skin substitutes is increasing owing to the technological advancements in healthcare, increasing prevalence of acute and chronic wounds, high demand of skin grafts, and rising awareness regarding various treatment options.

Increasing incidence of accidents such as road accidents, burns, and trauma events across the globe is also anticipated to drive the market for tissue engineered skin substitutes. For instance, as per WHO (2018), burn is the second most common injury in rural Nepal and it accounts for 5.0% of disabilities in the country. According to The American Burn Association, in 2016, 486,000 patients received burn injury treatment in U.S. Furthermore, as per the WHO, nearly 1.4 million people die from road traffic crashes every year. It also reported that road accident is the leading cause of death in children and adults aged 5 to 29 years. The skin grafts are majorly done for treatment of acute wounds. Biosynthetic and synthetic tissue engineered skin substitutes are used in the treatment of moderate and severe burns. Similarly, biological skin substitutes are used during the surgeries for healing large wounds. Thus, rising number of accidents is expected to boost the demand for tissue engineered skin substitutes, which is expected to lead to considerable market growth over the forecast period.

Increasing awareness level among people regarding various treatment options is also a key factor driving the market for tissue engineered skin substitutes over the forecast period. The market is also gaining pace owing to the rising willingness among the people to spend more and opt for new and advanced burn care products. Biosynthetic and synthetic skin grafts are majorly used for the treatment of moderate and severe burns. Biological tissue engineered skin substitutes are used for the treatment of first degree burn cases.

Presence of government organizations such as non-profit organization like American Burn Association (ABA) and World Health Organization (WHO) also contribute towards increasing the awareness levels. The WHO has been collaboratively working with The International Society for Burn Injuries (ISBI) and other such organizations to develop strategies to prevent burn injuries and improve burn care treatment globally. The U.S. Food and Drug Administration (FDA) follows pre-market approval process for scientific review of Class III devices to ensure safety and effectiveness of any medical product. Tissue engineered skin substitutes are classified under Class III medical devices. Some of the FDA approved tissue engineered skin substitutes are Apligraf, Dermagraft, and Integra Omnigraft Dermal Regeneration Matrix.

Furthermore, presence of non-profit organizations such as British Burn Association (BBA), which aims towards providing and propagating the knowledge on best treatment and rehabilitation following a burn injury and Canadian Association of Burn Nurses (CABN), which aims towards providing nurses who are expert in treating patients with burns are also increasing the awareness levels regarding burn care and treatment among the people.

Product Insights
On the basis of product, the market for tissue engineered skin substitutes has been segmented into biological, synthetic, and biosynthetic. The biological tissue engineered skin substitutes segment held the largest market share in 2019 owing to the rising prevalence of acute wounds across the globe. The major advantage of biological tissue engineered skin substitutes is that skin is readily available from the patient itself. Biological tissue engineered skin substitutes have more extracellular matrix, which aids in excellent re-epithelialization and faster healing of the wound.

The synthetic tissue engineered skin substitutes segment is anticipated to witness the fastest growth rate over the forecast period. The growth of segment is attributed to the rising technological advancements in the healthcare sector. Synthetic tissue engineered skin substitutes demonstrate more control over scaffold composition. Advancements in technology for development of tissue engineered skin substitutes such as collagen-synthetic bilaminates and tissue culture-derived membranes are contributing towards market growth.

Application Insights
On the basis of application, the tissue engineered skin substitutes market has been segmented into acute and chronic wounds. The acute wound segment held the largest market share in 2019 owing to the rising number of surgeries and increasing prevalence of burn injuries. As per the American Burn Association, in U.S., burn injuries are one of the major causes of unintentional injury and death. The segment has been further categorized into surgery and trauma, and burn injuries.

The chronic wound segment is anticipated to witness the fastest growth rate over the forecast period. Tissue engineered skin substitutes are majorly used in the treatment of extreme cases of diabetic foot ulcers, pressure ulcers, and venous leg ulcers. In this procedure, biological tissue engineered skin substitutes are majorly used in the grafting process.

End-Use Insights
The hospital segment held the largest revenue share in 2019 in the market for tissue engineered skin substitutes owing to the rising number of surgeries across the globe. The increasing cases of diabetic foot ulcers and venous leg ulcers are the major driving factors for the segment. In addition, increasing cases of surgical wounds due to rising number of surgeries is also driving the segment.

The wound care centers segment is anticipated to witness the significant growth over the forecast period. Wound care centers are the dedicated institutions for wound treatment. In many countries, wound care centers are still a new concept, but are rapidly gaining popularity. Therefore, this segment is anticipated to witness the significant growth over the forecast period.

Regional Insights
In North America, the market for tissue engineered skin substitutes held the largest revenue share in 2019 owing to the technological advancements in the healthcare sector, rising number of burn injuries, and presence of key players in the region. Increasing sports injuries, road accidents, and presence of several key players in the region are anticipated to drive the market in North America. In addition, availability of skilled professionals and improvement in healthcare infrastructure are also expected to drive the market in the region over the forecast period.

In Asia Pacific, the market is anticipated to witness fastest growth rate over the forecast period. Presence of developing countries such as China, India, and Japan is anticipated to boost market growth in the region. In addition, rapidly growing medical tourism industry in these countries can also be attributed to the increase in demand for tissue engineered skin substitutes in the region.

Key Companies & Market Share Insights
Key players are involved in adopting strategies such as merger and acquisitions, partnership, and launching new products to strengthen their foothold in the market. These players are investing heavily on research and development to manufacture technologically advanced products. Some of the prominent players in the tissue engineered skin substitutes market include:

Amarantus BioScience Holdings

Organogenesis, Inc.

KCI Licensing, Inc.

Smith and Nephew

BSN medical

Mölnlycke Health Care AB

Integra LifeSciences Corporation

Medtronic

Tissue Regenix

Segments Covered in the Report
This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2016 to 2027. For the purpose of this study, has segmented the global tissue engineered skin substitutes market report on the basis of products, application, end use, and region:

• Product Outlook (Revenue, USD Million, 2016 - 2027)

  • Synthetic

  • Biosynthetic

  • Biological

• Application Outlook (Revenue, USD Million, 2016 - 2027)

  • Acute Wounds

    • Surgery & Trauma

    • Burn Injuries

  • Chronic Wounds

    • Diabetic Foot Ulcers

    • Pressure Ulcers

    • Venous Leg Ulcers

    • Other Chronic Wounds

• End-Use Outlook (Revenue, USD Million, 2016 - 2027)

  • Hospitals

  • Wound Care Centers

  • Others

• Regional Outlook (Revenue, USD Million, 2016 - 2027)

  • North America

    • U.S.

    • Canada

  • Europe

    • U.K.

    • Germany

  • Asia Pacific

    • China

    • Japan

  • Latin America

    • Brazil

    • Mexico

  • MEA

    • South Africa

    • Saudi Arabia